We are committed to serving the best interests of our shareholders.

Filter Releases
 
Press Releases
Date Title and Summary View
1/11/2017 No concerns raised by FDA related to the rolapitant IV efficacy or safety profile and additional clinical studies are not requiredInvestor conference call and webcast scheduled for tomorrow at 8:30AM ET WALTHAM, Mass., Jan. 11, 2017 (GLOBE NEWSWIRE) -- ...
12/20/2016 Niraparib New Drug Application accepted for review by FDA with a PDUFA goal date of June 30, 2017Niraparib Expanded Access Program (EAP) expected to open in U.S. in January 2017 WALTHAM, Mass., Dec. 20, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO...
11/21/2016 WALTHAM, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences. The three conferences are: The Leerink POLARxPRESS Bus Tour at the Convene Conference...
11/15/2016 WALTHAM, Mass., Nov. 15, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has priced an underwritten public offering of an aggregate of 1,750,000 shares of its common stock at an offering price to the public of $135.00 per share. The gross proceeds from the offering will be approximately $236.3 mill...
11/14/2016 WALTHAM, Mass., Nov. 14, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) announced today that it has commenced an underwritten public offering of 1,750,000 shares of its common stock. In connection with this offering, TESARO plans to grant the underwriters an option to purchase up to an additional 262,000 shares of its common stock. Citi...
11/03/2016 Niraparib rolling NDA submission to FDA complete, MAA accepted for review by EMAPre-launch planning ongoing to support four potential product launches in 2017 across U.S. and EuropePositive Phase 3 NOVA trial results presented during Presidential Symposium at ESMO 2016 ...
11/01/2016 WALTHAM, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has completed the niraparib rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for the maintenance treatment of patients with platinum-s...
10/31/2016 WALTHAM, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of data from the ENGOT-OV16/NOVA trial of niraparib at the 2016 International Gynecologic Cancer Society (IGCS) Biennial Meeting in Lisbon, Portugal. These data were pre...
10/27/2016 WALTHAM, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Marketing Authorisation Application (MAA) for niraparib has been submitted to and accepted for review by the European Medicines Agency (EMA) for the maintenance treatment of pat...
10/24/2016 WALTHAM, Mass., Oct. 24, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences. The three conferences are:  The Credit Suisse 25th Annual Healthcare Conference at The Phoenician in Scotts...
= add release to Briefcase